Insider Selling: Audentes Therapeutics, Inc. (BOLD) SVP Sells $268,400.00 in Stock

Audentes Therapeutics, Inc. (NASDAQ:BOLD) SVP Mary Newman sold 10,000 shares of the firm’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $26.84, for a total value of $268,400.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Mary Newman also recently made the following trade(s):

  • On Thursday, August 24th, Mary Newman sold 10,000 shares of Audentes Therapeutics stock. The shares were sold at an average price of $20.00, for a total value of $200,000.00.

Shares of Audentes Therapeutics, Inc. (NASDAQ BOLD) opened at $27.57 on Monday. Audentes Therapeutics, Inc. has a twelve month low of $13.90 and a twelve month high of $33.43.

Audentes Therapeutics (NASDAQ:BOLD) last issued its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.88). research analysts predict that Audentes Therapeutics, Inc. will post -3.59 EPS for the current fiscal year.

WARNING: “Insider Selling: Audentes Therapeutics, Inc. (BOLD) SVP Sells $268,400.00 in Stock” was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://sportsperspectives.com/2017/11/20/insider-selling-audentes-therapeutics-inc-bold-svp-sells-268400-00-in-stock.html.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Redmile Group LLC increased its stake in Audentes Therapeutics by 77.8% during the second quarter. Redmile Group LLC now owns 1,459,616 shares of the biotechnology company’s stock worth $27,922,000 after acquiring an additional 638,780 shares during the last quarter. Jennison Associates LLC increased its stake in Audentes Therapeutics by 182.4% during the second quarter. Jennison Associates LLC now owns 846,273 shares of the biotechnology company’s stock worth $16,189,000 after acquiring an additional 546,617 shares during the last quarter. Perceptive Advisors LLC increased its stake in Audentes Therapeutics by 10.4% during the third quarter. Perceptive Advisors LLC now owns 781,309 shares of the biotechnology company’s stock worth $21,885,000 after acquiring an additional 73,809 shares during the last quarter. Vanguard Group Inc. increased its stake in Audentes Therapeutics by 130.3% during the second quarter. Vanguard Group Inc. now owns 678,412 shares of the biotechnology company’s stock worth $12,978,000 after acquiring an additional 383,837 shares during the last quarter. Finally, Alliancebernstein L.P. increased its stake in Audentes Therapeutics by 31.5% during the second quarter. Alliancebernstein L.P. now owns 640,654 shares of the biotechnology company’s stock worth $12,256,000 after acquiring an additional 153,617 shares during the last quarter. 83.01% of the stock is currently owned by institutional investors.

Several equities research analysts have recently issued reports on BOLD shares. Bank of America Corporation reaffirmed a “buy” rating and issued a $33.00 target price (up from $23.00) on shares of Audentes Therapeutics in a report on Friday, September 22nd. Zacks Investment Research cut Audentes Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Raymond James Financial, Inc. started coverage on Audentes Therapeutics in a report on Thursday, October 12th. They issued a “market perform” rating on the stock. ValuEngine cut Audentes Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, October 13th. Finally, William Blair started coverage on Audentes Therapeutics in a report on Tuesday, October 17th. They issued an “outperform” rating and a $35.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $27.17.

About Audentes Therapeutics

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Insider Buying and Selling by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply